

DAVID G. MANGUM (4085)  
C. KEVIN SPEIRS (5350)  
KRISTINE EDDE JOHNSON (7190)  
MICHAEL R. MCCARTHY (8850)  
PARSONS BEHLE & LATIMER  
One Utah Center  
201 South Main Street, Suite 1800  
Salt Lake City, UT 84111  
Telephone: (801) 532-1234  
Facsimile: (801) 536-6111  
[ecf@parsonsbehle.com](mailto:ecf@parsonsbehle.com)

BENJAMIN G. JACKSON (California Bar No 255358, *pro  
hac vice* motion to be filed)  
MATHEW GORDON (12526)  
MYRIAD GENETICS, INC.  
320 Wakara Way  
Salt Lake City, UT 84108  
[bjackson@myriad.com](mailto:bjackson@myriad.com)  
[mgordon@myriad.com](mailto:mgordon@myriad.com)  
*Attorneys for Plaintiffs*

**IN THE UNITED STATES DISTRICT COURT FOR THE  
DISTRICT OF UTAH, CENTRAL DIVISION**

UNIVERSITY OF UTAH RESEARCH  
FOUNDATION, a Utah nonprofit corporation; the  
TRUSTEES OF THE UNIVERSITY OF  
PENNSYLVANIA, a Pennsylvania nonprofit  
corporation; HSC RESEARCH AND  
DEVELOPMENT LIMITED PARTNERSHIP, a  
Canadian limited partnership organized under the laws  
of the Province of Ontario; ENDORECHERCHE,  
INC., a Canadian corporation organized under the laws  
of the Province of Quebec; and MYRIAD  
GENETICS, INC., a Delaware corporation;

Plaintiffs,

vs.

AMBRY GENETICS CORPORATION,

Defendant.

**FIRST AMENDED COMPLAINT  
DEMAND FOR JURY TRIAL**

Case No. 2:13-cv-00640-RJS

Judge Robert J. Shelby

**COMPLAINT FOR PATENT INFRINGEMENT**

1. Plaintiffs, University of Utah Research Foundation (“University of Utah”), The Trustees of the University of Pennsylvania (“University of Pennsylvania”), HSC Research and Development Limited Partnership (“Hospital for Sick Children”), Endorecherche, Inc. (“Endorecherche”), and Myriad Genetics, Inc. (“Myriad”), complain against Defendant Ambry Genetics Corporation (“Defendant”) as follows:

**JURISDICTION AND VENUE**

2. This civil action for patent infringement arises under the patent laws of the United States, specifically under Title 35 of the United States Code, Sections 271, *et seq.* Subject matter jurisdiction in this Court is founded upon 28 U.S.C. §§ 1331 and 1338(a).

3. This Court has personal jurisdiction over the Defendant because it regularly conducts business in this district and has committed acts in this judicial district which give rise to this action. On information and belief, Defendant sells, offers for sale, and has sold genetic testing products to residents of this jurisdiction. On information and belief, Defendant has attended, advertised, and or presented at conferences and/or meetings held in this jurisdiction in which it sells, offers for sale, has sold, and advertises its genetic testing products. On information and belief, Defendant has business relationships and/or has collaborated with multiple business and/or research entities in this district to which it sells, offers for sale, has sold, and/or advertises its genetic testing products. On information and belief, Defendant is a participating Medicaid and health insurance provider in this district.

4. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391(b), (c) and/or 28 U.S.C. § 1400(b).

**PARTIES**

5. The University of Utah is a Utah nonprofit corporation with an address at 421 Wakara Way, Suite 170, Salt Lake City, Utah 84108. The University of Utah is the owner or co-owner

of United States Patent Nos. 5,709,999; 5,747,282; 5,753,441; 5,837,492; and 6,033,857.

6. The University of Pennsylvania is a Pennsylvania nonprofit corporation with an address of 3160 Chestnut Street, Suite 200, Philadelphia, Pennsylvania 19104-6283. The University of Pennsylvania is a co-owner of United States Patent Nos. 6,033,857 and 5,837,492.

7. The Hospital for Sick Children is a Canadian limited partnership organized under the laws of the Province of Ontario, with an address of 555 University Avenue, Toronto, Ontario M5G 1X8, Canada. The Hospital for Sick Children is a co-owner of United States Patent Nos. 6,033,857 and 5,837,492.

8. Endorecherche is Canadian corporation organized under the laws of the Province of Quebec, with a place of business at 2989 De La Promenade, Ste-Foy, Quebec, QC G1W 2J5, Canada. Endorecherche is a co-owner of United States Patent Nos. 6,033,857 and 5,837,492.

9. Myriad is a Delaware corporation, with its principal place of business at 320 Wakara Way, Salt Lake City, Utah 84108. Myriad owns United States Patent Nos. 5,654,155; 5,750,400; 6,051,379; 6,951,721; 7,250,497, 7,670,776; and 7,563,571. As of July 1, 2013, Myriad owns United States Patent Nos. 7,622,258; and 7,838,237. As of July 19, 2013, Myriad owns United States Patent No. 7,470,510. Further, Myriad is the exclusive licensee of United States Patent Nos. 5,709,999; 5,747,282; 5,753,441; 5,837,492; and 6,033,857.

10. The Plaintiffs are informed and believe, and on that basis allege, that Defendant is a California corporation that has its principal place of business at 15 Argonaut, Aliso Viejo, California 92656.

### **GENERAL ALLEGATIONS**

11. Myriad is a molecular diagnostic company that develops and uses proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. Myriad's technologies result in, and guide the development of, new molecular diagnostic products that

assess an individual's risk for developing disease, identify a patient's likely response to drug therapy, and assess a patient's risk of disease progression and recurrence.

12. For healthcare providers, Myriad offers an array of genetic tests, prognostic tests and personalized medicine tests to help healthcare providers assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad's testing products provide healthcare providers with information to help make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient.

13. For patients, Myriad offers tests that provide important clinical information to assist patients and their healthcare providers in assessing cancer risk so the patient can take preventative action to reduce the risk of disease and in making treatment decisions if the patient is diagnosed with cancer. Myriad improves patient care through the development of new products across multiple medical specialties.

14. In the early-to-mid 1990s, Plaintiffs discovered the genetic sequences of the BRCA1 and BRCA2 genes and mutations that increase a woman's risk of developing breast and ovarian cancer. Since that time, Myriad has invested over \$500 million to implement this discovery and create a molecular diagnostic test for hereditary breast and ovarian cancer related to the BRCA1 and BRCA2 genes. Likewise, Myriad has spent significant resources to create a molecular diagnostic test for hereditary colon cancer caused by mutations in the mutY homolog (MYH) gene. Plaintiffs' efforts have revolutionized patient care and provided medical diagnosis and treatment options never thought possible.

15. Defendant offers laboratory services, including clinical diagnostic and genomic services, including testing and analysis of BRCA1, BRCA2, and MUTYH genes.

16. Defendant began offering its BRCA1 and BRCA2 analysis as part of its cancer-testing menu on June 13, 2013. On information and belief, Defendant offers stand-alone tests comprising full gene sequencing and deletion/duplication analyses for the BRCA 1, BRCA 2,

and MUTYH genes. On information and belief, Defendant also offers full gene sequencing and deletion/duplication analyses for the BRCA 1, BRCA 2, and MUTYH genes as part of multiple hereditary cancer panels that test cancer susceptibility using next-generation sequencing technology.

**FIRST CLAIM FOR RELIEF**

(By the University of Utah and Myriad for Infringement of United States Patent No. 5,709,999)

17. Plaintiffs repeat and reallege the allegations set forth in preceding paragraphs 1 through 16, inclusive.

18. United States Patent No. 5,709,999 (the “’999 Patent”), was duly and legally issued by the United States Patent and Trademark Office on January 20, 1998. The University of Utah is the owner and Myriad is the exclusive licensee of the ’999 Patent. A true and correct copy of the ’999 Patent is attached hereto and incorporated herein by reference as Exhibit 1.

19. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the ’999 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claim of the ’999 patent literally and/or under the doctrine of equivalents: Claim 6.

20. Plaintiffs have been damaged and have suffered irreparable injury due to the Defendant’s acts of infringement, and will continue to suffer irreparable injury unless Defendant’s acts are enjoined.

21. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant’s acts of patent infringement as alleged herein. The University of Utah has suffered and will continue to suffer substantial damage in the form of reduced royalty payments by reason of Defendant’s acts of patent

infringement and the resulting reduction in Myriad's sales revenues. Plaintiffs are entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

22. Defendant has willfully infringed the '999 Patent.

23. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

### **SECOND CLAIM FOR RELIEF**

(By the University of Utah and Myriad for Infringement of United States Patent No. 5,747,282)

24. Plaintiffs repeat and reallege the allegations set forth in preceding paragraphs 1 through 23, inclusive.

25. United States Patent No. 5,747,282 (the "'282 Patent"), was duly and legally issued by the United States Patent and Trademark Office on May 5, 1998. The University of Utah, along with the Public Health Service, through the National Institutes of Health ("PHS"), are the owners, and Myriad is the exclusive licensee, of the '282 Patent. A true and correct copy of the '282 Patent is attached hereto and incorporated herein by reference as Exhibit 2.

26. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '282 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claims of the '282 patent literally and/or under the doctrine of equivalents: Claims 6, 16, and 17.

27. Plaintiffs have been damaged and have suffered irreparable injury due to the Defendant's acts of infringement, and will continue to suffer irreparable injury unless Defendant's acts are enjoined.

28. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business

opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein. The University of Utah has suffered and will continue to suffer substantial damage in the form of reduced royalty payments by reason of Defendant's acts of patent infringement and the resulting reduction in Myriad's sales revenues. Plaintiffs are entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

29. Defendant has willfully infringed the '282 Patent.

30. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

### **THIRD CLAIM FOR RELIEF**

(By the University of Utah and Myriad for Infringement United States Patent No. 5,753,441)

31. Plaintiffs repeat and reallege the allegations set forth in preceding paragraphs 1 through 30, inclusive.

32. United States Patent No. 5,753,441 (the "'441 Patent"), was duly and legally issued by the United States Patent and Trademark Office on May 19, 1998. The University of Utah and PHS are the owners, and Myriad is the exclusive licensee, of the '441 Patent. A true and correct copy of the '441 Patent is attached hereto and incorporated herein by reference as Exhibit 3.

33. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '441 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claims of the '441 patent literally and/or under the doctrine of equivalents: Claims 7, 8, 12, 23, and 26.

34. Plaintiffs have been damaged and have suffered irreparable injury due to the Defendant's acts of infringement, and will continue to suffer irreparable injury unless Defendant's acts are enjoined.

35. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein. The University of Utah has suffered and will continue to suffer substantial damage in the form of reduced royalty payments by reason of Defendant's acts of patent infringement and the resulting reduction in Myriad's sales revenues. Plaintiffs are entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

36. Defendant has willfully infringed the '441 Patent.

37. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **FOURTH CLAIM FOR RELIEF**

(By the University of Utah, the University of Pennsylvania, and the Hospital for Sick Children, Endorecherche, and Myriad for Infringement of United States Patent No. 5,837,492)

38. Plaintiffs repeat and reallege the allegations set forth in preceding paragraphs 1 through 38, inclusive.

39. United States Patent No. 5,837,492 (the "'492 Patent'"), was duly and legally issued by the United States Patent and Trademark Office on November 17, 1998. The University of Utah, the University of Pennsylvania, the Hospital for Sick Children, and Endorecherche are the owners, and Myriad is the exclusive licensee, of the '492 Patent. A true and correct copy of the '492 Patent is attached hereto and incorporated herein by reference as Exhibit 4.

40. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '492 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claims of the '492 patent literally and/or under the doctrine of equivalents: Claims 29

and 30.

41. Plaintiffs have been damaged and have suffered irreparable injury due to the Defendant's acts of infringement, and will continue to suffer irreparable injury unless Defendant's acts are enjoined.

42. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein. The University of Utah, the University of Pennsylvania, the Hospital for Sick Children, and Endorecherche have suffered and will continue to suffer substantial damage in the form of reduced royalty payments by reason of Defendant's acts of patent infringement and the resulting reduction in Myriad's sales revenues. Plaintiffs are entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

43. Defendant has willfully infringed the '492 Patent.

44. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **FIFTH CLAIM FOR RELIEF**

(By the University of Utah, the University of Pennsylvania, the Hospital for Sick Children, Endorecherche, and Myriad for Infringement of United States Patent No. 6,033,857)

45. Plaintiffs repeat and reallege the allegations set forth in preceding paragraphs 1 through 44, inclusive.

46. United States Patent No. 6,033,857 (the "'857 Patent"), was duly and legally issued by the United States Patent and Trademark Office on March 7, 2000. The University of Utah, the University of Pennsylvania, the Hospital for Sick Children, and Endorecherche are the owners, and Myriad is the exclusive licensee, of the '857 Patent. A true and correct copy of the '857 Patent is attached hereto and incorporated herein by reference as Exhibit 5.

47. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '857 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claim of the '857 patent literally and/or under the doctrine of equivalents: Claim 4.

48. Plaintiffs have been damaged and have suffered irreparable injury due to the Defendant's acts of infringement, and will continue to suffer irreparable injury unless Defendant's acts are enjoined.

49. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein. The University of Utah, the University of Pennsylvania, the Hospital for Sick Children, and Endorecherche have suffered and will continue to suffer substantial damage in the form of reduced royalty payments by reason of Defendant's acts of patent infringement and the resulting reduction in Myriad's sales revenues. Plaintiffs are entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

50. Defendant has willfully infringed the '857 Patent.

51. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **SIXTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 5,654,155)

52. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 51, inclusive.

53. United States Patent No. 5,654,155 (the "'155 Patent"), was duly and legally issued by the United States Patent and Trademark Office on August 5, 1997. Myriad is the owner of the

'155 Patent. A true and correct copy of the '155 Patent is attached hereto and incorporated herein by reference as Exhibit 6.

54. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '155 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claims of the '155 patent literally and/or under the doctrine of equivalents: Claims 2, 3, and 4.

55. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

56. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

57. Defendant has willfully infringed the '155 Patent.

58. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **SEVENTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 5,750,400)

59. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 58, inclusive.

60. United States Patent No. 5,750,400 (the "'400 Patent"), was duly and legally issued by the United States Patent and Trademark Office on May 12, 1998. Myriad is the owner of the

'400 Patent. A true and correct copy of the '400 Patent is attached hereto and incorporated herein by reference as Exhibit 7.

61. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '400 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claims of the '400 patent literally and/or under the doctrine of equivalents: Claims 2, 3, 4, 5, 6, and 7.

62. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

63. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

64. Defendant has willfully infringed the '400 Patent.

65. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **EIGHTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 6,051,379)

66. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 65, inclusive.

67. United States Patent No. 6,051,379 (the "'379 Patent"), was duly and legally issued by the United States Patent and Trademark Office on April 18, 2000. Myriad is the owner of the

'379 Patent. A true and correct copy of the '379 Patent is attached hereto and incorporated herein by reference as Exhibit 8.

68. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '379 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claims of the '379 patent literally and/or under the doctrine of equivalents: Claims 32 and 33.

69. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

70. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

71. Defendant has willfully infringed the '379 Patent.

72. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **NINTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 6,951,721)

73. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 73, inclusive.

74. United States Patent No. 6,951,721 (the "'721 Patent"), was duly and legally issued by the United States Patent and Trademark Office on October 5, 2005. Myriad is the owner of

the '721 Patent. A true and correct copy of the '721 Patent is attached hereto and incorporated herein by reference as Exhibit 9.

75. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '721 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claim of the '721 patent literally and/or under the doctrine of equivalents: Claim 5.

76. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

77. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

78. Defendant has willfully infringed the '721 Patent.

79. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **TENTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 7,250,497)

80. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 79, inclusive.

81. United States Patent No. 7,250,497 (the "'497 Patent"), was duly and legally issued by the United States Patent and Trademark Office on July 31, 2007. Myriad is the owner of the '497 Patent. A true and correct copy of the '497 Patent is attached hereto and incorporated

herein by reference as Exhibit 10.

82. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '497 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, and CancerNext products that infringe at least the following claims of the '497 patent literally and/or under the doctrine of equivalents: Claims 3, 4, 5, 6, 7, 8, 11, 14, 17, 18, and 19.

83. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

84. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

85. Defendant has willfully infringed the '497 Patent.

86. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **ELEVENTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 7,470,510)

87. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 86, inclusive.

88. United States Patent No. 7,470,510 (the "'510 Patent"), was duly and legally issued by the United States Patent and Trademark Office on December 30, 2008. Myriad is the owner of the '510 Patent. A true and correct copy of the '510 Patent is attached hereto and incorporated

herein by reference as Exhibit 11.

89. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '510 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BreastNext, OvaNext, CancerNext, ColoNext, MUTYH-Associated Polyposis, and Familial Adenomatous Polyposis Panel products that infringe at least the following claims of the '510 patent literally and/or under the doctrine of equivalents: Claims 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18.

90. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

91. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

92. Defendant has willfully infringed the '510 Patent.

93. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

**TWELVTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 7,622,258)

94. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 93, inclusive.

95. United States Patent No. 7,622,258 (the "'258 Patent"), was duly and legally issued by the United States Patent and Trademark Office on November 24, 2009. Myriad is the owner

of the '258 Patent. A true and correct copy of the '258 Patent is attached hereto and incorporated herein by reference as Exhibit 12.

96. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '258 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BreastNext, OvaNext, CancerNext, ColoNext, MUTYH-Associated Polyposis, and Familial Adenomatous Polyposis Panel products that infringe at least the following claims of the '258 patent literally and/or under the doctrine of equivalents: Claims 10, 11, 15, 16, 17, and 19.

97. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

98. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

99. Defendant has willfully infringed the '258 Patent.

100. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

### **THIRTEENTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 7,838,237)

101. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 100, inclusive.

102. United States Patent No. 7,838,237 (the "'237 Patent"), was duly and legally issued by the United States Patent and Trademark Office on November 23, 2010. Myriad is the owner

of the '237 Patent. A true and correct copy of the '237 Patent is attached hereto and incorporated herein by reference as Exhibit 13.

103. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '237 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BreastNext, OvaNext, CancerNext, ColoNext, MUTYH-Associated Polyposis, and Familial Adenomatous Polyposis Panel products that infringe at least the following claims of the '237 patent literally and/or under the doctrine of equivalents: Claims 2, 8, and 16.

104. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

105. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

106. Defendant has willfully infringed the '237 Patent.

107. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **FOURTEENTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 7,670,776)

108. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 107, inclusive.

109. United States Patent No. 7,670,776 (the "'776 Patent"), was duly and legally issued by the United States Patent and Trademark Office on March 2, 2010. Myriad is the owner of the

'776 Patent. A true and correct copy of the '776 Patent is attached hereto and incorporated herein by reference as Exhibit 14.

110. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '776 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BreastNext, OvaNext, CancerNext, ColoNext, MUTYH-Associated Polyposis, and Familial Adenomatous Polyposis Panel products that infringe at least the following claims of the '776 patent literally and/or under the doctrine of equivalents: Claims 2, 3, 5, 9, 10, and 12.

111. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

112. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

113. Defendant has willfully infringed the '776 Patent.

114. Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

#### **FIFTEENTH CLAIM FOR RELIEF**

(By Myriad for Infringement of United States Patent No. 7,563,571)

115. Plaintiff Myriad repeats and realleges the allegations set forth in preceding paragraphs 1 through 114, inclusive.

116. United States Patent No. 7,563,571 (the "'571 Patent"), was duly and legally issued by the United States Patent and Trademark Office on July 21, 2009. Myriad is the owner of the

'571 Patent. A true and correct copy of the '571 Patent is attached hereto and incorporated herein by reference as Exhibit 15.

117. Defendant is infringing, contributing to the infringement of, and/or inducing others to infringe the '571 patent by making, manufacturing, promoting, marketing, advertising, distributing, offering for sale and selling and/or causing to be offered or sold certain BreastNext, OvaNext, CancerNext, ColoNext, MUTYH-Associated Polyposis, and Familial Adenomatous Polyposis Panel products that infringe at least the following claims of the '571 patent literally and/or under the doctrine of equivalents: Claims 2 and 7.

118. Myriad has been damaged and has suffered irreparable injury due to the Defendant's acts of infringement, and Myriad will continue to suffer irreparable injury unless Defendant's acts are enjoined.

119. Myriad has suffered and will continue to suffer substantial damage to its business, including, without limitation, lost profits, loss of business reputation, loss of business opportunities, and loss of market share, by reason of Defendant's acts of patent infringement as alleged herein, and Myriad is entitled to recover from Defendant the damages sustained as a result of Defendant's acts.

120. Defendant has willfully infringed the '571 Patent.

Defendant's acts make this an exceptional case within the meaning of 35 U.S.C. § 285.

**DEMAND FOR JURY TRIAL**

121. Plaintiffs demand a trial by jury on all matters herein so triable.

**RELIEF REQUESTED**

WHEREFORE, Plaintiffs pray for Judgment as follows:

a. That Defendant has infringed, contributed to the infringement of, and induced infringement of, literally and/or under the doctrine of equivalents, the asserted claims of the '999, '282, '441, '492, '857, '155, '400, '379, '721, '497, '510, '258, '237, '776, and '571

patents;

b. That Defendant and its subsidiaries, affiliates, parents, successors, assigns, officers, agents, servants, employees, attorneys, and all other persons acting in concert or in participation with it, be temporarily and preliminarily enjoined during the pendency of this action, and permanently enjoined thereafter, from infringing the '999, '282, '441, '492, '857, '155, '400, '379, '721, '497, '510, '258, '237, '776, and '571 patents, and specifically from directly or indirectly making, using, selling, offering for sale, or importing any products or services embodying the inventions of the '999, '282, '441, '492, '857, '155, '400, '379, '721, '497, '510, '258, '237, '776, and '571 patents, including, without limitation, the Defendant's BRCA1, BRCA2, BRCAPlus, BreastNext, OvaNext, CancerNext, ColoNext, MUTYH-Associated Polyposis, and Familial Adenomatous Polyposis Panel products, during the life of the claims of the '999, '282, '441, '492, '857, '155, '400, '379, '721, '497, '510, '258, '237, '776, and '571 patents without Plaintiffs' express written authority;

c. That Plaintiffs be awarded all damages attributable to Defendant's infringement of the '999, '282, '441, '492, '857, '155, '400, '379, '721, '497, '510, '258, '237, '776, and '571 patents in an amount according to proof at trial, but not less than a reasonable royalty;

d. That Defendant be ordered to deliver to Plaintiffs, for destruction at Plaintiffs' option, all products that infringe the '999, '282, '441, '492, '857, '155, '400, '379, '721, '497, '510, '258, '237, '776, and '571 patents;

e. That Defendant be required to account for all gains, profits, advantages, and unjust enrichment derived from their violations of the law;

f. That this case be deemed "exceptional" within the meaning of 35 U.S.C. § 285;

g. That Plaintiffs be awarded their reasonable attorneys' fees incurred in connection with this matter;

h. That Plaintiffs be awarded enhanced damages and/or costs pursuant to 35 U.S.C.

§ 285 and/or applicable law;

- i. That Plaintiffs be awarded the costs of suit, and an assessment of interest; and,
- j. That the Court award Plaintiffs such other, further, and different relief as the evidence may require and as the Court deems proper under the circumstances.

DATED this 19th day of July, 2013.

/s/ David G. Mangum

DAVID G. MANGUM

C. KEVIN SPEIRS

KRISTINE EDDE JOHNSON

MICHAEL R. MCCARTHY

PARSONS BEHLE & LATIMER

BENJAMIN G. JACKSON

MATHEW GORDON

*Attorneys for Plaintiffs*

Plaintiffs' Addresses:

University of Utah Research Foundation  
Technology Transfer Office  
421 Wakara Way, Suite 170  
Salt Lake City, UT 84108

University of Pennsylvania  
Center for Technology Transfer  
3160 Chestnut Street, Suite 200  
Philadelphia, PA 19104-6283

HSC Research and Development Limited Partnership  
555 University Avenue  
Toronto, Ontario M5G 1X8  
Canada

Endorecherche, Inc.  
2989 De La Promenade  
Ste-Foy, Quebec, QC G1W 2J5  
Canada

Myriad Genetics, Inc.  
320 Wakara Way  
Salt Lake City, UT 84108

**CERTIFICATE OF SERVICE**

On this 19th day of July 2013, I certify that I electronically filed the foregoing **PLAINTIFFS' FIRST AMENDED COMPLAINT DEMAND FOR JURY** with the Clerk of Court using the CM/ECF system that will send an electronic notification to counsel of record for all of the parties.

/s/ David G. Mangum